Nestle to buy Aimmune Therapeutics for $2.6 billion

ZURICH (Reuters) – Nestle (NESN.S) said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics (AIMT.O) it does not already own, adding a potential blockbuster to its health science portfolio.

The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million Nestle had already invested in Aimmune, Nestle said in a statement.


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments